Open Access
CC BY 4.0 · Pharmaceutical Fronts 2025; 07(01): e41-e52
DOI: 10.1055/a-2522-0009
Original Article

Computational Exploration of Multitarget Effects of Curcumin in Breast Cancer Treatment

Siddhartha Bethi
1   Shree P.E. (Tatya) Patil Institute of Pharmacy, Jalgaon, Maharashtra, India
,
Rahul Shirole
2   A.R.A. College of Pharmacy, Nagaon, Dhule, Maharashtra, India
,
Gauri Ghangale
3   Amrutvahini College of Pharmacy, Sangamner, Pune, Maharashtra, India
,
Subhasri Mohapatra
4   Royal College of Pharmacy, Raipur, Chhattisgarh, India
,
Asmita Gaikwad
5   Sharadchandra Pawar College of Pharmacy, Otur, Pune, Maharashtra, India
,
Harshal Tare
5   Sharadchandra Pawar College of Pharmacy, Otur, Pune, Maharashtra, India
› Author Affiliations

Funding None.
Preview

Abstract

Curcumin, a bioactive compound derived from Curcuma longa, has shown promising potential in breast cancer therapy due to its multitarget pharmacological effects. This study aimed to explore the molecular mechanisms underlying curcumin's anticancer activity using an integrative computational approach, including predictive modeling, molecular docking, and pathway enrichment analysis. Curcumin demonstrated strong binding affinities to critical targets such as matrix metalloproteinase-9 (MMP9), protein kinase B (AKT1), epidermal growth factor receptor (EGFR), and signal transducer and activator of transcription 3 (STAT3), which are implicated in pathways regulating cancer cell survival, proliferation, invasion, and metastasis. Gene Ontology and Kyoto Encyclopedia of Genes and Genomes pathway analyses revealed curcumin's ability to modulate processes like apoptosis, inflammation, and cell signaling, emphasizing its therapeutic versatility. Molecular docking and dynamics simulations further validated its stable interactions with key targets. Complementing the computational findings, in vitro studies using MCF-7 breast cancer cells confirmed curcumin's dose-dependent cytotoxic effects. These results highlight curcumin's potential as a complementary therapeutic agent in breast cancer management, and in vivo studies are needed to substantiate its clinical utility in further studies.



Publication History

Received: 20 September 2024

Accepted: 21 January 2025

Article published online:
03 March 2025

© 2025. The Author(s). This is an open access article published by Thieme under the terms of the Creative Commons Attribution License, permitting unrestricted use, distribution, and reproduction so long as the original work is properly cited. (https://creativecommons.org/licenses/by/4.0/)

Georg Thieme Verlag KG
Oswald-Hesse-Straße 50, 70469 Stuttgart, Germany